

Roni Shouval

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2311873/roni-shouval-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

596
papers

9,172
citations

46
h-index

75
g-index

659
ext. papers

12,409
ext. citations

4.5
avg, IF

5.95
L-index

#	Paper	IF	Citations
596	Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia.. <i>Cancer Medicine</i> , 2022 ,	4.8	1
595	Evaluating outcomes of adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma treated on the GMALL 07/2003 protocol.. <i>Annals of Hematology</i> , 2022 , 101, 581	3	0
594	A Randomized, Phase 3, Trial of Interferon- β versus Hydroxyurea in Polycythemia Vera and Essential Thrombocythemia.. <i>Blood</i> , 2022 ,	2.2	6
593	An instructive role for Interleukin-7 receptor β in the development of human B-cell precursor leukemia.. <i>Nature Communications</i> , 2022 , 13, 659	17.4	3
592	ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy.. <i>Annals of Hematology</i> , 2022 , 101, 309-316	3	1
591	Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B cell lymphoma.. <i>Transplantation and Cellular Therapy</i> , 2022 ,		3
590	Impact of Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy. <i>Journal of Clinical Oncology</i> , 2021 , JCO2102143	2.2	2
589	Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. <i>Leukemia</i> , 2021 , 35, 3585-3588	10.7	12
588	Long-Term Outcome of Peripheral Blood Autologous Stem Cell Transplantation (AutoSCT) for De Novo Acute Myeloid Leukemia in Patients Achieving First Complete Remission after One Vs Two Induction Courses: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2021 , 138, 1810-1818	2.2	
587	Lesion Characteristics and Patterns of Failure in Diffuse Large B Cell Lymphoma Patients Treated with Bridging Radiotherapy Prior to Chimeric Antigen Receptor T Cell Therapy. <i>Blood</i> , 2021 , 138, 1429-1429	2.2	
586	An improved index for diagnosis and mortality prediction in malignancy associated hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2021 ,	2.2	8
585	Novel Agents May be Preferable to Chemotherapy for Large B-Cell Lymphoma Progressing after CD19-CAR-T: A Multicenter Observational Study. <i>Blood</i> , 2021 , 138, 883-883	2.2	1
584	Higher Efficacy of TBI + Cyclophosphamide Than TBI + Fludarabine As Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2021 , 138, 2876-2876	2.2	0
583	Primary Central Nervous System Involvement at Initial Diagnosis Remains an Independent Risk Factor for Relapse in Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation in CR1. <i>Blood</i> , 2021 , 138, 2901-2901	2.2	
582	Graft-Versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021 ,		1
581	Encouraging Survival and High Rates of Toxicity: Allogeneic Hematopoietic Cell Transplantation after Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Aggressive Lymphoma Patients. <i>Blood</i> , 2021 , 138, 910-910	2.2	0
580	KIR-HLA Interactions Lack Clinical Utility in Matched Unrelated Donor Transplantation for AML: An Analysis of the CIBMTR and DRST Registries. <i>Blood</i> , 2021 , 138, 419-419	2.2	

579	Poor Outcome of Patients with COVID-19 after CAR T-Cell Therapy for B-Cell Malignancies: Results from a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. <i>Blood</i> , 2021 , 138, 2818-2818	2.2	
578	ELN 2017 Classification Significantly Impacts on the Risk of Early Death in Acute Myeloid Leukemia Patients Receiving Intensive Induction Chemotherapy. <i>Blood</i> , 2021 , 138, 3392-3392	2.2	
577	Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy. <i>Blood</i> , 2021 , 138, 3390-3390	2.2	
576	Five-Year Experience Using Bridging Radiotherapy Prior to Chimeric Antigen Receptor (CAR) T-Cell Therapies for B-Cell Malignancies at Memorial Sloan Kettering Cancer Center. <i>Blood</i> , 2021 , 138, 2507-2507 ²	2.2	
575	Allogeneic Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia (AML) in Second Complete Remission (CR2) Transplanted from Unrelated Donors with Post Transplant Cyclophosphamide (PTCy). a Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Blood</i> , 2021 , 138, 3915-3915	2.2	
574	Isocitrate Dehydrogenase (IDH) 1 and 2 Mutation Is an Independent Predictor of Better Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Study of the ALWP of EBMT. <i>Blood</i> , 2021 , 138, 2920-2920	2.2	0
573	Venetoclax Reverses Metabolic Reprogramming Induced By S1P Modulator FTY720, Suppresses Oxidative Phosphorylation and Synergistically Targets Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1195-1195	2.2	
572	TP53 and CD19-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma. <i>Blood</i> , 2021 , 138, 710-710	2.2	0
571	The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations. <i>Bone Marrow Transplantation</i> , 2021 ,	4.4	2
570	Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021 ,	4.4	1
569	Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1800-1813	15.1	11
568	Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prophylaxis in Alternative Donor Stem Cell Transplantation: Immune Reconstitution and Infection Risk. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 883-884		0
567	Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients. <i>British Journal of Haematology</i> , 2021 ,	4.5	6
566	The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 233-240		7
565	Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1842-1849	4.4	0
564	Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1900-1907	4.4	7
563	Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. <i>Lancet Haematology</i> , 2021 , 8, e205-e215	14.6	5
562	Outcome of T-cell-replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2021 , 127, 2507-2514	6.4	2

561	Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021 , 193, 592-601	4.5	3
560	Allogeneic haematopoietic cell transplantation for myelofibrosis: a real-life perspective. <i>British Journal of Haematology</i> , 2021 , 195, 495-506	4.5	1
559	Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. <i>Clinical Cancer Research</i> , 2021 , 27, 3695-3703	12.9	1
558	Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2194-2202	4.4	1
557	The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy. <i>British Journal of Haematology</i> , 2021 , 193, 1060-1075	4.5	4
556	Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 76	22.4	9
555	Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT. <i>Blood Cancer Journal</i> , 2021 , 11, 88	7	1
554	Feasibility and Outcomes of a Third Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 408.e1-408.e6		0
553	Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 76	22.4	2
552	Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2445-2453	4.4	1
551	Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 84	22.4	4
550	A novel index using inflammatory markers improves the diagnosis of hemophagocytic lymphohistiocytosis in patients with hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7563-7563	2.2	1
549	Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia. <i>Cancers</i> , 2021 , 13,	6.6	1
548	Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. <i>Haematologica</i> , 2021 ,	6.6	3
547	Complete Remission with Incomplete Blood Count Recovery Is a Strong Predictor of Nonrelapse Mortality in Acute Myeloid Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Acta Haematologica</i> , 2021 , 144, 613-619	2.7	0
546	High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2690-2696	4.4	0
545	Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation. <i>International Journal of Hematology</i> , 2021 , 114, 363-372	2.3	0
544	Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia. <i>Haematologica</i> , 2021 , 106, 1591-1598	6.6	10

543	The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study. <i>Bone Marrow Transplantation</i> , 2021 , 56, 20-29	4.4	0
542	Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2021 , 56, 532-535	4.4	21
541	Multiple Myeloma Presenting in Patients Younger than 50 Years of Age: A Single Institution Experience. <i>Acta Haematologica</i> , 2021 , 144, 58-65	2.7	2
540	Machine learning and artificial intelligence in haematology. <i>British Journal of Haematology</i> , 2021 , 192, 239-250	4.5	17
539	Common gene variants within 3'-untranslated regions as modulators of multiple myeloma risk and survival. <i>International Journal of Cancer</i> , 2021 , 148, 1887-1894	7.5	1
538	Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia. <i>Clinical Cancer Research</i> , 2021 , 27, 843-851	12.9	11
537	Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 218-224	4.4	10
536	Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021 , 56, 622-634	4.4	2
535	Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1077-1085	4.4	1
534	BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. <i>Cancer</i> , 2021 , 127, 1246-1259	6.4	6
533	Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Cancer Medicine</i> , 2021 , 10, 23-33	4.8	2
532	Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 171.e1-171.e8		2
531	Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1134-1143	4.4	6
530	Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1190-1199	4.4	5
529	A phase II study of bisantrene in patients with relapsed/refractory acute myeloid leukemia. <i>European Journal of Haematology</i> , 2021 , 106, 260-266	3.8	1
528	Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1047-1055	4.4	0
527	Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1272-1280	4.4	7
526	Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2021 , 56, 917-927	4.4	2

525	Carfilzomib combined with cyclosporine and methotrexate for the prevention of graft-versus-host disease after allogeneic stem-cell transplantation from unrelated donors. <i>Bone Marrow Transplantation</i> , 2021 , 56, 451-456	4.4	
524	Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. <i>Journal of Clinical Oncology</i> , 2021 , 39, 121-131	4.4	0
523	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 6-20		12
522	How we can mitigate the side effects associated with systemic glucocorticoid after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1248-1256	4.4	3
521	Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment. <i>Journal of Cancer</i> , 2021 , 12, 5423-5431	4.5	2
520	Primum non nocere: allo-HSCT for AML in CR1. <i>Blood</i> , 2021 , 137, 438-439	2.2	
519	How Do We Manage Hematopoietic Cell Transplant during the SARS-CoV-2 Pandemic?. <i>Acta Haematologica</i> , 2021 , 144, 500-507	2.7	1
518	Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT. <i>European Journal of Haematology</i> , 2021 , 106, 708-715	3.8	
517	Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1692-1701	1.9	5
516	Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma. <i>Blood Advances</i> , 2021 , 5, 823-828	7.8	8
515	CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study. <i>Cancer Immunology Research</i> , 2021 , 9, 1061-1070	12.5	8
514	Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 831-840	2	1
513	Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. <i>Blood Advances</i> , 2021 , 5, 3397-3406	7.8	7
512	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 110-118		4
511	Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. <i>British Journal of Haematology</i> , 2021 195, 417-428	4.5	2
510	Predicting 30-day mortality after ST elevation myocardial infarction: Machine learning-based random forest and its external validation using two independent nationwide datasets. <i>Journal of Cardiology</i> , 2021 , 78, 439-446	3	4
509	Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission. <i>Bone Marrow Transplantation</i> , 2020 , 55, 2244-2253	4.4	1
508	Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 46	22.4	24

507	Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 42	22.4	24
506	Resveratrol Enhances mRNA and siRNA Lipid Nanoparticles Primary CLL Cell Transfection. <i>Pharmaceutics</i> , 2020 , 12,	6.4	8
505	Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation. <i>American Journal of Hematology</i> , 2020 , 95, 1135	7.1	1
504	Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1784-1802	4.7	5
503	CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges. <i>Current Research in Translational Medicine</i> , 2020 , 68, 111-118	3.7	24
502	Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 87	22.4	11
501	Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. <i>Lancet Haematology,the</i> , 2020 , 7, e284-e294	14.6	36
500	Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. <i>Lancet Haematology,the</i> , 2020 , 7, e157-e167	14.6	116
499	LDH and renal function are prognostic factors for long-term outcomes of multiple myeloma patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1736-1743	4.4	6
498	Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 296-304	2	3
497	Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells. <i>Leukemia</i> , 2020 , 34, 1939-1942	10.7	9
496	Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1093-1102	4.4	30
495	Decision-analytic modeling as a tool for selecting optimal therapy incorporating hematopoietic stem cell transplantation in patients with hematological malignancy. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1220-1228	4.4	1
494	CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1525-1532	4.4	11
493	Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response. <i>Molecular Carcinogenesis</i> , 2020 , 59, 736-744	5	15
492	Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib. <i>EJHaem</i> , 2020 , 1, 94-102	0.9	6
491	Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients 2020 , 8,		21
490	CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT). <i>American Journal of Hematology</i> , 2020 , 95, 888-898	7.1	4

489	Reduced Intensity Vs. Non-Myeloablative Conditioning Regimens for Haploidentical Transplantation in Complete Remission Acute Myeloid Leukemia: A Study from the ALWP of the EBMT. <i>Blood</i> , 2020 , 136, 9-9	2.2	
488	A Novel Inflammatory Index Is Sufficient to Identify Hemophagocytic Lymphohistiocytosis in Adult Patients with Hematologic Malignancies. <i>Blood</i> , 2020 , 136, 1-2	2.2	
487	Use of Post-Transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Results in Similar Transplant Outcomes Than Haploidentical Hransplantation: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2020 , 136, 26-27	2.2	
486	Comparison of Reduced Intensity Conditioning - Allogeneic HCT and Autologous HCT for Elderly Patients with Acute Lymphoblastic Leukemia. an Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Blood</i> , 2020 , 136, 6-7	2.2	
485	Evaluating Outcomes of Adult Patients with Acute Lymphoblastic Leukemia Treated on the GMALL Protocol. <i>Blood</i> , 2020 , 136, 28-29	2.2	
484	Outcomes of Allogeneic Hematopoietic Cell Transplantation with Cord Blood Versus Mismatched Unrelated Donor with Post-Transplant Cyclophosphamide in Acute Myeloid Leukemia: An Analysis from the ALWP of the EBMT. <i>Blood</i> , 2020 , 136, 5-6	2.2	
483	A Phase II Study of Bisantrene in Patients with Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2020 , 136, 5-6	2.2	
482	CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma: a Safety and Efficacy Study. <i>Blood</i> , 2020 , 136, 34-34	2.2	9
481	Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia. <i>Oncotarget</i> , 2020 , 11, 2233-2245	3.3	1
480	Summary of Scientific and Statistical Methods, Study Endpoints and Definitions for Observational and Registry-Based Studies in Hematopoietic Cell Transplantation. <i>Clinical Hematology International</i> , 2020 , 2, 2-4	1.8	19
479	COVID-19 in Hematologic Malignancies: Big Challenges. <i>Clinical Hematology International</i> , 2020 , 2, 173-175		2
478	Weathering the storm: COVID-19 infection in patients with hematological malignancies. <i>Journal of Zhejiang University: Science B</i> , 2020 , 21, 921-939	4.5	2
477	Mechanism of HPSE Gene SNPs Function: From Normal Processes to Inflammation, Cancerogenesis and Tumor Progression. <i>Advances in Experimental Medicine and Biology</i> , 2020 , 1221, 231-249	3.6	1
476	Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. <i>Leukemia</i> , 2020 , 34, 2766-2775	10.7	10
475	Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1114-1125	4.4	28
474	Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study. <i>Leukemia</i> , 2020 , 34, 128-137	10.7	17
473	Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. <i>American Journal of Hematology</i> , 2020 , 95, 151-155	7.1	19
472	The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2020 , 34, 1144-1153	10.7	4

471	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Bone Marrow Transplantation</i> , 2020 , <i>55</i> , 181-191	4.4	22
470	Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , <i>26</i> , 936-942	4.7	9
469	Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia. <i>Current Research in Translational Medicine</i> , 2020 , <i>68</i> , 17-22	3.7	11
468	Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. <i>American Journal of Hematology</i> , 2020 , <i>95</i> , 362-371	7.1	50
467	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Haematologica</i> , 2020 , <i>105</i> , 297-316	6.6	122
466	Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2020 , <i>131</i> , 1031-1037	6.4	7
465	Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years. <i>Clinical Cancer Research</i> , 2020 , <i>26</i> , 6475-6482	12.9	9
464	Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , <i>20</i> , e947-e955	2	4
463	Patterns of salivary microbiota injury and oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation. <i>Blood Advances</i> , 2020 , <i>4</i> , 2912-2917	7.8	16
462	Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , <i>26</i> , 1915-1922	4.7	14
461	Progression of disease within 24 months of initial therapy (POD24) detected incidentally in imaging does not necessarily indicate worse outcome. <i>Leukemia and Lymphoma</i> , 2020 , <i>61</i> , 2645-2651	1.9	1
460	Impact of total body irradiation- vs chemotherapy-based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2020 , <i>95</i> , 1200	7.1	6
459	Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response. <i>Journal of Hematology and Oncology</i> , 2020 , <i>13</i> , 158	22.4	6
458	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020 , <i>4</i> , 3180-3190	7.8	4
457	FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , <i>26</i> , 1923-1930	4.7	4
456	Outcome of parosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. <i>Haematologica</i> , 2020 , <i>105</i> , 193-200	6.6	12
455	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. <i>Bone Marrow Transplantation</i> , 2020 , <i>55</i> , 485-495	4.4	28
454	Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥0 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT. <i>Bone Marrow Transplantation</i> , 2020 , <i>55</i> , 729-739	4.4	1

453	Personalizing rabbit anti-thymocyte globulin therapy for prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation: is there an optimal dose?. <i>Bone Marrow Transplantation</i> , 2020 , 55, 505-522	4.4	9
452	Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT. <i>Leukemia</i> , 2020 , 34, 283-292	10.7	28
451	Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT. <i>Leukemia</i> , 2020 , 34, 87-99	10.7	11
450	Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. <i>Bone Marrow Transplantation</i> , 2020 , 55, 126-136	4.4	82
449	Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis. <i>Bone Marrow Transplantation</i> , 2020 , 55, 147-156	4.4	5
448	Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. <i>Blood Advances</i> , 2020 , 4, 676-686	7.8	51
447	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2020 , 105, 47-58	6.6	25
446	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with -internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2020 , 105, 1507-1511	6.6	34
445	Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 108	22.4	33
444	Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2113-2123	4.7	38
443	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2305-2321	4.7	68
442	A novel method for detecting the cellular stemness state in normal and leukemic human hematopoietic cells can predict disease outcome and drug sensitivity. <i>Leukemia</i> , 2019 , 33, 2061-2077	10.7	8
441	Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. <i>Haematologica</i> , 2019 , 104, 929-936	6.6	12
440	Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16). <i>Genes Chromosomes and Cancer</i> , 2019 , 58, 516-520	5	4
439	Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. <i>Lancet Haematology</i> , 2019 , 6, e89-e99	14.6	31
438	Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemia. <i>Cancer</i> , 2019 , 125, 3566-3573	6.4	12
437	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1975-1983	4.7	32
436	Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019 , 54, 2013-2019	4.4	6

435	Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2019 , 186, 767-776	4.5	10
434	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). <i>Bone Marrow Transplantation</i> , 2019 , 54, 1747-1755	4.4	55
433	A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2404-2414	1.9	8
432	Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia. <i>Leukemia</i> , 2019 , 33, 1944-1952	10.7	15
431	Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. <i>Leukemia</i> , 2019 , 33, 2324-2330	10.7	18
430	Fertility preservation from the point of view of hematopoietic cell transplant specialists-a worldwide-web-based survey analysis. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1747-1755	4.4	4
429	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1525-1552	4.4	128
428	Shaping of CD56 Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis. <i>Frontiers in Immunology</i> , 2019 , 10, 547	8.4	7
427	Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis. <i>Haematologica</i> , 2019 , 104, 1782-1788	6.6	26
426	Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide. <i>Leukemia</i> , 2019 , 33, 230-239	10.7	26
425	European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation. <i>Leukemia</i> , 2019 , 33, 508-517	10.7	24
424	Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis. <i>Bone Marrow Transplantation</i> , 2019 , 54, 531-539	4.4	13
423	Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2019 , 54, 519-530	4.4	36
422	Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. <i>Bone Marrow Transplantation</i> , 2019 , 54, 44-52	4.4	43
421	Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia. <i>EClinicalMedicine</i> , 2019 , 15, 33-41	11.3	7
420	Haploidentical stem cell transplantation (HaploSCT) for patients with acute leukemia-an update on behalf of the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2019 , 54, 713-718	4.4	8
419	The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators. <i>Biochemical Pharmacology</i> , 2019 , 168, 412-428	6	6
418	A simplified method for detection of N-terminal valine adducts in patients receiving treosulfan. <i>Rapid Communications in Mass Spectrometry</i> , 2019 , 33, 1635-1642	2.2	6

417	Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2251-2260	4.7	10
416	Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2008-2016	4.7	9
415	Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 68	22.4	9
414	Risk factors and implications of oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2019 , 103, 402-409	3.8	18
413	The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	15
412	Safety, Resistance, and Efficacy Results from a Phase IIIb Study of Conventional- and Double-Dose Oseltamivir Regimens for Treatment of Influenza in Immunocompromised Patients. <i>Infectious Diseases and Therapy</i> , 2019 , 8, 613-626	6.2	13
411	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. <i>Leukemia</i> , 2019 , 33, 2767-2778	10.7	34
410	Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. <i>Lancet Haematology</i> , 2019 , 6, e573-e584	14.6	71
409	Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma. <i>Blood</i> , 2019 , 134, 1531-1531	2.2	2
408	Lactate Dehydrogenase Is a Key Prognostic Factor in Acute Myeloid Leukemia and Lymphoma Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2019 , 134, 3304-3304	2.2	3
407	Predictive Model of Early Relapse in Newly Diagnosed Multiple Myeloma: Analysis from a Pooled Dataset. <i>Blood</i> , 2019 , 134, 2130-2130	2.2	1
406	Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells. <i>Blood</i> , 2019 , 134, 1947-1947	2.2	2
405	Upregulation of Senescent/Exhausted Phenotype of CAR T Cells and Induction of Both Treg and Myeloid Suppressive Cells Correlate with Reduced Response to CAR T Cell Therapy in Relapsed/Refractory B Cell Malignancies. <i>Blood</i> , 2019 , 134, 3234-3234	2.2	6
404	Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies. <i>Blood</i> , 2019 , 134, 4009-4009	2.2	6
403	Current Status and Perspectives of Irradiation-Based Conditioning Regimens for Patients with Acute Leukemia Undergoing Hematopoietic Stem Cell Transplantation. <i>Clinical Hematology International</i> , 2019 , 1, 19-27	1.8	10
402	Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia: T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study. <i>Clinical Hematology International</i> , 2019 , 1, 58-74	1.8	26
401	Fecal Microbiota Transplantation for Treatment of Acute Graft-Host Disease. <i>Clinical Hematology International</i> , 2019 , 1, 28-35	1.8	9
400	Long-term follow-up of patients (pts) with relapsed or refractory (r/r) follicular lymphoma (FL) treated with copanlisib.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 7553-7553	2.2	

399	Immunophenotyping and Function of Peripheral Blood Mononuclear Cells in Patients Undergoing Unrelated Allogeneic Transplantation with Post-Transplantation Cyclophosphamide in Combination with ATG Anti-Graft Versus Host Disease Prophylaxis. <i>Blood</i> , 2019 , 134, 1989-1989	2.2	
398	Oral Mucositis Is Associated with Distinctive Patterns of Oral Microbiota Injury in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2019 , 134, 3265-3265	2.2	0
397	Maintaining the Cellular Anti-Viral and Anti-Leukemic Activities in GvHD Patients Undergoing Extracorporeal Photophoresis Therapy. <i>Blood</i> , 2019 , 134, 3287-3287	2.2	
396	Early Organ Toxicity Following Allogeneic Hematopoietic Stem Cell Transplantation Differs By Conditioning Regimen. <i>Blood</i> , 2019 , 134, 4489-4489	2.2	1
395	Comparing Gradings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management. <i>Blood</i> , 2019 , 134, 4458-4458	2.2	
394	Early and late hematologic toxicity following CD19 CAR-T cells. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1643-1650	4.4	114
393	Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI. <i>Blood Advances</i> , 2019 , 3, 1950-1960	7.8	7
392	External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation. <i>Blood Advances</i> , 2019 , 3, 1881-1890	7.8	37
391	Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT. <i>Blood Cancer Journal</i> , 2019 , 9, 88	7	13
390	PAR1 Expression Predicts Clinical G-CSF CD34 HSPC Mobilization and Repopulation Potential in Transplanted Patients. <i>HemaSphere</i> , 2019 , 3, e288	0.3	2
389	HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 114-120	4.7	14
388	ASBMT Statement on Routine Prophylaxis for Central Nervous System Recurrence of Acute Lymphoblastic Leukemia Following Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, e86-e88	4.7	4
387	Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia. <i>Leukemia</i> , 2019 , 33, 686-695	10.7	14
386	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, e100-e100	4.7	53
385	Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT. <i>European Journal of Cancer</i> , 2019 , 106, 212-219	7.5	6
384	Deferasirox selectively induces cell death in the clinically relevant population of leukemic CD34CD38 cells through iron chelation, induction of ROS, and inhibition of HIF1 β expression. <i>Experimental Hematology</i> , 2019 , 70, 55-69.e4	3.1	12
383	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT. <i>British Journal of Haematology</i> , 2019 , 184, 782-787	4.5	37
382	Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. <i>Lancet Haematology</i> , 2019 , 6, e67-e78	14.6	95

381	Reply: Letter to the Editor Regarding "Autologous Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis". <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, e114-e115		47
380	Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma. <i>Acta Haematologica</i> , 2019 , 141, 84-90	2.7	6
379	Anti- $\alpha 4\beta 7$ integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2019 , 54, 987-993	4.4	24
378	Is fluorescence in-situ hybridization sufficient in patients with myelodysplastic syndromes and insufficient cytogenetic testing?. <i>Leukemia and Lymphoma</i> , 2019 , 60, 764-771	1.9	3
377	The effect of NIMA matching in adult unrelated mismatched hematopoietic stem cell transplantation - a joint study of the Acute Leukemia Working Party of the EBMT and the CIBMTR. <i>Bone Marrow Transplantation</i> , 2019 , 54, 849-857	4.4	0
376	Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission. <i>American Journal of Hematology</i> , 2019 , 94, 231-239	7.1	7
375	Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1001-1009	4.4	17
374	Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology	4.7	8
373	T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2018 , 93, 736-744	7.1	15
372	Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome. <i>Leukemia Research</i> , 2018 , 68, 9-14	2.7	10
371	AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation. <i>Bone Marrow Transplantation</i> , 2018 , 53, 683-691	4.4	10
370	Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 1357-1366	4.9	6
369	Attenuated DNA damage responses and increased apoptosis characterize human hematopoietic stem cells exposed to irradiation. <i>Scientific Reports</i> , 2018 , 8, 6071	4.9	15
368	Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT. <i>European Journal of Haematology</i> , 2018 , 61, 73-81	7.5	24
367	Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMT. <i>American Journal of Hematology</i> , 2018 , 93, 859-866	7.1	16
366	Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 937-944	4.7	25
365	Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2018 , 53, 617-624	4.4	30
364	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018 , 24, 282-291	50.5	144

363	Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018 , 53, 535-555	4.4	47
362	Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2224-2232	4.7	28
361	Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. <i>Bone Marrow Transplantation</i> , 2018 , 53, 422-430	4.4	15
360	The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. <i>Bone Marrow Transplantation</i> , 2018 , 53, 521-534	4.4	94
359	Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Haematology</i> , 2018 , 5, e34-e43	14.6	57
358	Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1548-1552	4.4	4
357	Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. <i>British Journal of Haematology</i> , 2018 , 181, 760-769	4.5	26
356	Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy. <i>Haematologica</i> , 2018 , 103, e469-e472	6.6	65
355	ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1119-1124	4.7	15
354	The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. <i>Haematologica</i> , 2018 , 103, 1191-1197	6.6	52
353	Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study. <i>American Journal of Hematology</i> , 2018 , 93, 769-777	7.1	16
352	Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1139-1148	4.4	93
351	Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 1102-1114	9.7	30
350	Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1463-1470	4.7	22
349	Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2224-2232	4.7	32
348	Identification of strong intron enhancer in the heparanase gene: effect of functional rs4693608 variant on HPSE enhancer activity in hematological and solid malignancies. <i>Oncogenesis</i> , 2018 , 7, 51	6.6	12
347	Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2224-2232	4.7	8
346	Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018 , 93, 1211-1219	7.1	17

345	Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2018 , 93, 1142-1152	7.1	54
344	Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2265-2270	4.7	5
343	Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2365-2370	4.7	38
342	Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1406-1414	4.7	28
341	Baseline Renal Function and Albumin are Powerful Predictors for Allogeneic Transplantation-Related Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1685-1691	4.7	10
340	Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>British Journal of Haematology</i> , 2018 , 178, 144-153	4.5	17
339	Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 533-540	2	7
338	Repeated Courses of Orally Administered Fecal Microbiota Transplantation for the Treatment of Steroid Resistant and Steroid Dependent Intestinal Acute Graft Vs. Host Disease: A Pilot Study (NCT 03214289). <i>Blood</i> , 2018 , 132, 2121-2121	2.2	4
337	Incidence of Acute Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation over Time: A Study from the Transplant Complications and Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2018 , 132, 2120-2120	2.2	5
336	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. <i>Blood</i> , 2018 , 132, 2022-2022	2.2	6
335	Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET). <i>Blood</i> , 2018 , 132, 577-577	2.2	32
334	Incidence of HLA Loss in a Global Multicentric Cohort of Post-Transplantation Relapses: Results from the Hlaloss Collaborative Study. <i>Blood</i> , 2018 , 132, 818-818	2.2	8
333	Inferior Outcome of Allogeneic Stem Cell Transplantation in First Complete Remission for Secondary AML As Compared to De Novo Disease: Results from a Retrospective, Registry-Based Analysis on Behalf of the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2018 , 132, 2166-2166	2.2	1
332	Post-Transplant Sorafenib Improves Overall Survival in FLT3 Mutated AML: A Report from the EBMT Acute Leukemia Working Party. <i>Blood</i> , 2018 , 132, 708-708	2.2	3
331	Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma. <i>Blood</i> , 2018 , 132, 1595-1595	2.2	9
330	Outcomes for Patients with High-Risk Relapsed or Refractory Indolent B-Cell Lymphoma Treated with Copanlisib in the CHRONOS-1 Study. <i>Blood</i> , 2018 , 132, 395-395	2.2	4
329	Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma. <i>Blood</i> , 2018 , 132, 1613-1613	2.2	1
328	Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses of diabetic patients from the phase II CHRONOS-1 study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7570-7570	2.2	1

327	Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission. <i>Oncotarget</i> , 2018 , 9, 3379-3393	3.3	28
326	STK405759 as a combination therapy with bortezomib or dexamethasone, in and multiple myeloma models. <i>Oncotarget</i> , 2018 , 9, 31367-31379	3.3	4
325	Single cell analysis of multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8026-8026	2.2	
324	Comorbidity-Associated Risk of Overall Mortality Following Hematopoietic Stem-Cell Transplantation Is Regimen-Dependent: A Study from the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2018 , 132, 203-203	2.2	
323	No Inhibition of Anti-Viral and Anti-Leukemia Effects By Extracorporeal Photopheresis Therapy. <i>Blood</i> , 2018 , 132, 3399-3399	2.2	1
322	Outcome of Soft-Tissue Plasmacytomas in Newly Diagnosed Multiple Myeloma Patients Treated with New Drugs. <i>Blood</i> , 2018 , 132, 3235-3235	2.2	
321	The Role of Anti-Thymocyte Globulin (ATG) in Patients with AML Transplanted in CR1 from Sibling and Unrelated Donors with or without Measurable Residual Disease (MRD) at the Time of Allogeneic Stem Cell Transplantation: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Blood</i> , 2018 , 132, 248-248	2.2	1
320	FLT3 and NPM1 Are Powerful Determinants of Outcome in Acute Myeloid Leukemia Patients Treated with Autologous Stem Cell Transplantation: An Analysis By the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2018 , 132, 609-609	2.2	
319	Inhibition of WIP1 Phosphatase in Multiple Myeloma Overcomes Bortezomib Resistance and Promotes Cell Death Via ER Stress-Induced Apoptotic JNK/c-Jun Signaling and Downregulation of Inhibitors of Apoptosis Proteins (IAPs). <i>Blood</i> , 2018 , 132, 1366-1366	2.2	
318	Ibrutinib, Bendamustine, Rituximab Combination for Relapsed and Refractory Aggressive B Cell Lymphoma [Interim Analysis of Phase II Clinical Trial. <i>Blood</i> , 2018 , 132, 4186-4186	2.2	0
317	Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 507-513	4.7	5
316	Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. <i>American Journal of Hematology</i> , 2018 , 93, 246-253	7.1	29
315	Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. <i>Nature Medicine</i> , 2018 , 24, 1867-1876	50.5	105
314	Single-Dose Daily Fractionation Is Not Inferior to Twice-a-Day Fractionated Total-Body Irradiation Before Allogeneic Stem Cell Transplantation for Acute Leukemia: A Useful Practice Simplification Resulting From the SARASIN Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, 515-526	4	13
313	Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 132, 9-16	7	11
312	Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects. <i>Frontiers in Immunology</i> , 2018 , 9, 2207	8.4	9
311	Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 127	22.4	13
310	Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT. <i>American Journal of Hematology</i> , 2018 , 93, 1532-1542	7.1	8

309	Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2018 , 93, 1485-1492	7.1	61
308	Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 110	22.4	29
307	Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?. <i>Blood Advances</i> , 2018 , 2, 1180-1186	7.8	23
306	Prevention and treatment of relapse after stem cell transplantation with immunotherapy. <i>Bone Marrow Transplantation</i> , 2018 , 53, 664-672	4.4	8
305	Role of oral examination in newly diagnosed multiple myeloma patients: A safe and simple way to detect light chain amyloidosis. <i>Oral Diseases</i> , 2018 , 24, 1343-1348	3.5	5
304	CAR T cells induce a complete response in refractory Burkitt Lymphoma. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1583-1585	4.4	12
303	The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation. <i>Leukemia</i> , 2018 , 32, 1787-1794	10.7	16
302	Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantation-a retrospective national multicenter study. <i>Annals of Hematology</i> , 2017 , 96, 575-579	3	5
301	The gastrointestinal tract: properties and role in allogeneic hematopoietic stem cell transplantation. <i>Expert Review of Hematology</i> , 2017 , 10, 315-326	2.8	6
300	Gender disparities in the functional significance of anemia among apparently healthy adults. <i>European Journal of Haematology</i> , 2017 , 98, 435-442	3.8	4
299	High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation. <i>Haematologica</i> , 2017 , 102, 160-167	6.6	32
298	Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT. <i>Cancer</i> , 2017 , 123, 1965-1970	6.4	23
297	Validation of the acute leukemia-EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi-center GITMO cohort. <i>American Journal of Hematology</i> , 2017 , 92, 429-434	7.1	23
296	Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2017 , 102, 1066-1074	6.6	29
295	Isolated Extramedullary Relapse of Acute Leukemia after Allogeneic Stem Cell Transplantation: Different Kinetics and Better Prognosis than Systemic Relapse. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1087-1094	4.7	33
294	Peroxisome proliferator-activated receptor gamma (PPAR γ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target. <i>EMBO Molecular Medicine</i> , 2017 , 9, 508-530	12	10
293	ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT. <i>American Journal of Hematology</i> , 2017 , 92, 789-796	7.1	11
292	Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission-Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Cancer</i> , 2017 , 123, 881-884	6.4	23

291	Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning. <i>American Journal of Hematology</i> , 2017 , 92, 1011-1019	7.1	7
290	Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT. <i>American Journal of Hematology</i> , 2017 , 92, 653-659	7.1	10
289	Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients. <i>Blood Cells, Molecules, and Diseases</i> , 2017 , 65, 1-7	2.1	19
288	Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2017 , 102, 224-234	6.6	61
287	The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors. <i>American Journal of Hematology</i> , 2017 , 92, 259-268	7.1	8
286	Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT. <i>American Journal of Hematology</i> , 2017 , 92, 244-250	7.1	9
285	Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. <i>Haematologica</i> , 2017 , 102, 1913-1922	6.6	34
284	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. <i>Blood</i> , 2017 , 130, 2610-2618	2.2	69
283	Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2017 , 102, 2134-2140	6.6	20
282	Ethnic variation in medical and lifestyle risk factors for B cell non-Hodgkin lymphoma: A case-control study among Israelis and Palestinians. <i>PLoS ONE</i> , 2017 , 12, e0171709	3.7	11
281	From patient centered risk factors to comprehensive prognostic models: a suggested framework for outcome prediction in umbilical cord blood transplantation. <i>Stem Cell Investigation</i> , 2017 , 4, 39	5.1	4
280	Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34 Cells in Healthy Volunteers. <i>Clinical Cancer Research</i> , 2017 , 23, 6790-6801	12.9	26
279	Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission. <i>American Journal of Hematology</i> , 2017 , 92, 1318-1323	7.1	17
278	Machine learning for prediction of 30-day mortality after ST elevation myocardial infraction: An Acute Coronary Syndrome Israeli Survey data mining study. <i>International Journal of Cardiology</i> , 2017 , 246, 7-13	3.2	47
277	An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia. <i>Clinical Cancer Research</i> , 2017 , 23, 6478-6486	12.9	21
276	Prognostic Scoring Systems in Allogeneic Hematopoietic Stem Cell Transplantation: Where Do We Stand?. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1839-1846	4.7	17
275	Long-Term Outcomes of Cord Blood Transplantation from an HLA-Identical Sibling for Patients with Bone Marrow Failure Syndromes: A Report From Eurocord, Cord Blood Committee and Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1839-1848	4.7	14
274	Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 278-284	4.7	27

273	Ponatinib reduces viability, migration, and functionality of human endothelial cells. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1455-1467	1.9	35
272	The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway. <i>Clinical Cancer Research</i> , 2017 , 23, 1733-1747	12.9	26
271	Salvage High-Dose Chemotherapy for Relapsed Pure Seminoma in the Last 10 Years: Results From the European Society for Blood and Marrow Transplantation Series 2002-2012. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 163-167	3.3	2
270	Identification of miRSNPs associated with the risk of multiple myeloma. <i>International Journal of Cancer</i> , 2017 , 140, 526-534	7.5	6
269	Allogeneic Stem Cell Transplantation for Patients Age \geq 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 44-52	4.7	36
268	Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT. <i>British Journal of Haematology</i> , 2017 , 171, 131-138	4.5	20
267	Long-Term Safety of Transplanting Human Bone Marrow Stromal Cells into the Extravascular Spaces of the Choroid of Rabbits. <i>Stem Cells International</i> , 2017 , 2017, 4061975	5	5
266	Copanlisib in patients with relapsed or refractory follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7535-7535	2.2	3
265	Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Oncotarget</i> , 2017 , 8, 418-429	3.3	5
264	Dissecting the mechanisms involved in anti-human T-lymphocyte immunoglobulin (ATG)-induced tolerance in the setting of allogeneic stem cell transplantation - potential implications for graft versus host disease. <i>Oncotarget</i> , 2017 , 8, 90748-90765	3.3	4
263	Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT. <i>Oncotarget</i> , 2017 , 8, 112972-112979	3.3	13
262	The CXCR4 Antagonist BL-8040 Induces a Robust Mobilization of CD34+CD38 ^{low} CD45RA ^{low} CD90+ CD49f+ HSCs with Long-Term and Secondary Myeloid and Lymphoid Repopulating Activity. <i>Blood</i> , 2017 , 130, 660-660	2.2	1
261	Transplantation Outcome By Disease Risk and Donor Type over Time: An Analysis of 100,000 Allogeneic Stem Cell Transplantation on Behalf of the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2017 , 130, 668-668	2.2	
260	Donor Age Determines Outcome in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Cell Transplantation. <i>Blood</i> , 2017 , 130, 850-850	2.2	
259	Outcomes of Graft Failures after Umbilical Cord Blood Transplantation in Acute Leukemia: A Study from Eurocord and the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2017 , 130, 661-661	2.2	
258	Haploidentical T-Repleted Stem Cell Transplantation (SCT) Has Comparable Survival to 10/10 and 9/10 Unrelated SCT in Poor-Cytogenetics Risk Acute Myeloid Leukemia in First Complete Remission: A Study on Behalf of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2017 , 130, 852-852	2.2	
257	Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study. <i>Leukemia and Lymphoma</i> , 2016 , 57, 63-9	1.9	20
256	Established and emerging targeted therapies in the myelodysplastic syndromes. <i>Expert Review of Hematology</i> , 2016 , 9, 997-1005	2.8	1

255	Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. <i>Haematologica</i> , 2016 , 101, 879-83	6.6	90
254	Unmanipulated haploidentical versus matched unrelated donor allogeneic stem cell transplantation in adult patients with acute myelogenous leukemia in first remission: a retrospective pair-matched comparative study of the Beijing approach with the EBMT database. <i>Blood</i> , 2016 , 128, 1502-1509	6.6	31
253	Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. <i>Journal of Hematology and Oncology</i> , 2016 , 9, 118	22.4	40
252	Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD. <i>Blood</i> , 2016 , 128, 1979-1986	2.2	49
251	Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 277-283	4.7	11
250	Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications. <i>Expert Review of Hematology</i> , 2016 , 9, 297-314	2.8	30
249	Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 23-6	4.7	46
248	Reprint of: Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, S15-8	4.7	17
247	VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 329-334.e1	2	22
246	Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E16-22	11.5	57
245	Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 43-53	59.2	321
244	The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia. <i>Blood</i> , 2016 , 128, 2745-2745	2.2	3
243	Comparison of Allogeneic Stem Cell Transplantation for Transformed Acute Myeloid Leukemia Derived from MDS, CMML or MPN. a Report of the Chronic Malignancies Working Party of EBMT. <i>Blood</i> , 2016 , 128, 3499-3499	2.2	2
242	Impact of Immune Reconstitution (IR) and Graft-Versus-Host Disease (GvHD) on Clinical Outcomes after Treatment with Donor T Cells Transduced to Express the Herpes Simplex Virus Thymidine-Kinase Suicide Gene (TK cells) in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016 , 128, 1502-1502	2.2	2
241	Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia. <i>Blood</i> , 2016 , 128, 479-479	2.2	20
240	Primary Plasma Cell Leukemia Has a Poor Prognosis Even in the Era of Novel Agents - a Multicenter Case Series. <i>Blood</i> , 2016 , 128, 5699-5699	2.2	1
239	An EBMT Prospective Non-Interventional Study of Outcomes and Toxicity of Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second Generation Tyrosine Kinase Inhibitors. <i>Blood</i> , 2016 , 128, 628-628	2.2	1
238	Allogeneic Genetically Modified T Cells (HSV-TK) As Adjunctive Treatment in Haploidentical Hematopoietic Stem-Cell Transplantation (haplo-HSCT) of Adult Patients with High-Risk Hematological Malignancies: A Pair-Matched Analysis from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2016 , 128, 672-672	2.2	5

237	Autologous Hematopoietic Cell Transplantation in Elderly Patients Aged 65 and Older: A Retrospective Analysis By the Complications and Quality of Life Working Party of the EBMT. <i>Blood</i> , 2016 , 128, 678-678	2.2	7
236	The Disease Risk Index Is a Robust Tool for Allogeneic Hematopoietic Stem Cell Transplantation Risk Stratification: An Independent Validation Study on a Large Cohort of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016 , 128, 988-988	2.2	1
235	Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8018-8018	2.2	8
234	Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study. <i>PLoS ONE</i> , 2016 , 11, e0150637	3.7	20
233	The novel compound STK405759 is a microtubule-targeting agent with potent and selective cytotoxicity against multiple myeloma in vitro and in vivo. <i>Oncotarget</i> , 2016 , 7, 62572-62584	3.3	3
232	High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2167-2174	3.3	40
231	The High Affinity CXCR4 Inhibitor, BL-8040, Induces Apoptosis of AML Blasts and Their Terminal Differentiation By Blocking AKT/ERK Survival Signals and Downregulating BCL-2, MCL-1 and Cyclin-D1 through Regulation of Mir-15a/16-1 Expression. <i>Blood</i> , 2016 , 128, 767-767	2.2	
230	Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT. <i>Blood</i> , 2016 , 128, 3467-3467	2.2	
229	Objective Measures of Pre-Transplant Physiologic Fitness Are Strong Predictors of Very-Short Term Transplantation Related Mortality. <i>Blood</i> , 2016 , 128, 2205-2205	2.2	
228	Prediction of Allogeneic Stem Cell Transplantation Mortality in Patients with Acute Leukemia (AL) Using the AL- European Society for Blood and Marrow Transplantation (EBMT) Risk Score in the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO) Data Set: A Study on Behalf of the AL Working Party (ALWP) of the EBMT. <i>Journal of Clinical Oncology</i> , 2016 , 34, 200-200	2.2	
227	Impact of FAB Classification on Predicting Outcome in Acute Myeloid Leukemia, Not Otherwise Specified, Patients Undergoing Allogeneic Stem Cell Transplantation in CR1: An Analysis of 1690 Patients from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2016 , 128, 2899-2899	2.2	
226	A Comparison of Fractionated Myeloablative Total Body Irradiation Schedules Combined with Chemotherapy As Conditioning for Allograft Bone Marrow Transplantation in Patients with Acute Leukemia: The Sarasin Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016 , 128, 3497-3497	2.2	
225	Development of a Risk Score for Prediction of Overall Survival Following Umbilical Cord Blood Transplantation in Acute Leukemia Patients: A Study from the Acute Leukemia Working Party (WP) and Paediatric Disease WP of the European Society for Blood and Marrow Transplantation (EBMT), and Eurocord. <i>Blood</i> , 2016 , 128, 1169-1169	2.2	
224	An Alternative Donor Is a Valid Option Compared to a Matched-Unrelated in Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in CR2: A Report of 841 Patients from the EBMT Acute Leukemia Working Party. <i>Blood</i> , 2016 , 128, 3497-3497	2.2	
223	Use of First or Second Generation TKI for CML after Allogeneic Stem Cell Transplantation: a Study By the CMWP of the EBMT. <i>Blood</i> , 2016 , 128, 4685-4685	2.2	2
222	The Use of Anti-Thymocyte Globulin Is Associated with Increased Chance of Survival Free from Relapse and Graft-Versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation for Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2016 , 128, 666-666	2.2	
221	The Neglected Role of Hematologic Disorders in Pulmonary Embolism. <i>Journal of Cardiovascular Emergencies</i> , 2016 , 2, 192-193	0.3	
220	Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. <i>Haematologica</i> , 2016 , 101, 256-62	6.6	33

219	Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. <i>Cancer</i> , 2016 , 122, 2050-6	6.4	30
218	Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?. <i>Genes Chromosomes and Cancer</i> , 2016 , 55, 710-8	5	15
217	Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2016 , 122, 2941-51	6.4	97
216	Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2016 , 122, 2941-51	6.4	26
215	Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease status. <i>Haematologica</i> , 2016 , 101, e34-7	6.6	7
214	Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2016 , 101, 773-80	6.6	30
213	Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMT. <i>Oncologist</i> , 2016 , 21, 377-83	5.7	7
212	Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies. <i>Annals of Medicine</i> , 2016 , 48, 428-439	1.5	26
211	Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT. <i>Haematologica</i> , 2016 , 101, 248-55	6.6	15
210	Peripheral blood stem cell versus bone marrow transplantation: A perspective from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Experimental Hematology</i> , 2016 , 44, 567-73	3.1	16
209	Associations between B-cell non-Hodgkin lymphoma and exposure, persistence and immune response to hepatitis B. <i>Haematologica</i> , 2016 , 101, e303-5	6.6	8
208	Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2016 , 9, 79	22.4	28
207	Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>European Journal of Haematology</i> , 2016 , 96, 92-7	3.8	15
206	Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2141-54	2.2	83
205	Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2015 , 100, 859-69	6.6	62
204	Predictive Limitations of Hematopoietic Stem Cell Transplantation Associated Mortality: A Machine Learning in-Silico Analysis of the EBMT - Acute Leukemia Working Party Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, S310-S311	4.7	2
203	Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2015 , 16, 1525-1536	21.7	103
202	Epiretinal transplantation of human bone marrow mesenchymal stem cells rescues retinal and vision function in a rat model of retinal degeneration. <i>Stem Cell Research</i> , 2015 , 15, 387-94	1.6	35

201	Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1852-5	4.7	3
200	Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, e95-9	2	14
199	Chemotherapy dose adjustment for obese patients undergoing hematopoietic stem cell transplantation: a survey on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Oncologist</i> , 2015 , 20, 50-5	5.7	5
198	T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysis. <i>Haematologica</i> , 2015 , 100, 558-64	6.6	25
197	Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. <i>Blood</i> , 2015 , 126, 2062-9	2.2	71
196	The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2015 , 100, 683-9	6.6	29
195	Economics and Outcome After Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. <i>EBioMedicine</i> , 2015 , 2, 2101-9	8.8	28
194	Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT). <i>American Journal of Hematology</i> , 2015 , 90, 719-24	7.1	14
193	Bioactive magnetic near Infra-Red fluorescent core-shell iron oxide/human serum albumin nanoparticles for controlled release of growth factors for augmentation of human mesenchymal stem cell growth and differentiation. <i>Journal of Nanobiotechnology</i> , 2015 , 13, 34	9.4	35
192	Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. <i>Lancet Haematology</i> , 2015 , 2, e384-92	14.6	33
191	Halofuginone inhibits phosphorylation of SMAD-2 reducing angiogenesis and leukemia burden in an acute promyelocytic leukemia mouse model. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015 , 34, 65	12.8	10
190	Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Leukemia Research</i> , 2015 , 39, 933-7	2.7	18
189	Effect of cord blood processing on transplantation outcomes after single myeloablative umbilical cord blood transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 688-95	4.7	15
188	Phase 3, Placebo-Controlled, ASPIRE Study (TRC114968) of Eltrombopag (EPAG) Treatment of Thrombocytopenia (TCP) in Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Assessment of Clinical Benefit, Safety, and Tolerability. <i>Blood</i> , 2015 , 126, 1661-1661	2.2	1
187	Roneparstat (SST0001), an Innovative Heparanase (HPSE) Inhibitor for Multiple Myeloma (MM) Therapy: First in Man Study. <i>Blood</i> , 2015 , 126, 3246-3246	2.2	10
186	HLA Disparities Impact on Outcomes after Unmanipulated Haploidentical Hematopoietic Stem Cells Transplantation (HaploSCT) in Acute Leukemia: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2015 , 126, 399-399	2.2	2
185	Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and May Lead to Eradication of Measureable Disease. <i>Blood</i> , 2015 , 126, 4218-4218	2.2	10
184	An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study. <i>Blood</i> , 2015 , 126, 827-827	2.2	15

183	Impact of response to induction chemotherapy (CT) and prior paclitaxel (TXL)-based CT on the outcome of salvage high-dose chemotherapy (HDCT) for relapsed germ-cell tumors (GCT) in the modern era: An EBMT Solid Tumors Working Party study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4535-4535	2.2	
182	Conventional-dose (CDCT) versus high-dose chemotherapy (HDCT) in the salvage management of relapsed pure seminoma: Results from an international database.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15559-e15559	2.2	
181	Evaluation of the Impact of Non-Inherited Maternal Antigens on the Outcome of HLA Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation for Hematological Malignancies on Behalf of the ALWP of the EBMT and the CIBMTR. <i>Blood</i> , 2015 , 126, 3226-3226	2.2	
180	Allogeneic Stem Cell Transplantation for Elderly Patients with Intermediate-Risk Cytogenetic Acute Myeloid Leukemia and Internal Tandem Duplication of FLT3 (FLT3-ITD); A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2015 , 126, 4364-4364	2.2	
179	Outcome of Patients with Myelofibrosis Relapsing after Allogeneic Stem Cell Transplant: A Retrospective Study By the Chronic Malignancies Working Party of EBMT. <i>Blood</i> , 2015 , 126, 1958-1958	2.2	
178	A Machine Learning Based Model to Predict Two-Year Leukemia Free Survival in Cord Blood Transplantation for Acute Leukemia - a Data Mining Study, on Behalf of Eurocord, Cord Blood Committee and the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2015 , 126, 3211-3211	2.2	1
177	Anti-Human T-Lymphocyte Immunoglobulin (ATG)-Induced T Regulatory Cells and Their Soluble Factors Suppress T Cell Proliferation: Potential Role in Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2015 , 126, 1889-1889	2.2	
176	Autologous Stem Cell Transplantation for Adult Acute Myelocytic Leukemia in First Remission: Better Outcome Following Busulfan and Melphalan Compared to Busulfan and Cyclophosphamide : A Retrospective Study from the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2015 , 126, 926-926	2.2	
175	Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with High-Risk AML in Complete Remission: A Survey from the ALWP of the EBMT. <i>Blood</i> , 2015 , 126, 3105-3105	2.2	
174	Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia and 17p Abnormalities in First Complete Remission: A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2015 , 126, 2021-2021	2.2	
173	Thiotepa-Based Conditioning for Allogeneic Stem Cell Transplantation (allo-HSCT) in Acute Lymphoblastic Leukaemia (ALL) - a Survey from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2015 , 126, 4316-4316	2.2	
172	Comparison of Matched-Sibling Donors Versus Unrelated Donors in Allogeneic Stem Cell Transplantation (allo-SCT) for Primary Refractory Acute Myeloid Leukemia (PRF AML): A Report of 1041 Patients from the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2015 , 126, 196-196	2.2	
171	STK405759 As a Novel Tubulin Active Agent for Multiple Myeloma Therapy. <i>Blood</i> , 2015 , 126, 5348-5348	2.2	
170	Allogeneic Stem Cell Transplantation for MDS Patients More Than 70 Years of Age: a Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party (CMWP) of the EBMT. <i>Blood</i> , 2015 , 126, 4390-4390	2.2	1
169	Transplantation of human bone marrow mesenchymal stem cells as a thin subretinal layer ameliorates retinal degeneration in a rat model of retinal dystrophy. <i>Experimental Eye Research</i> , 2014 , 118, 135-44	3.7	94
168	Nilotinib 300 mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular response. <i>Leukemia Research</i> , 2014 , 38, 310-5	2.7	11
167	Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 58-65	4.7	36
166	NK cell receptor NKp46 regulates graft-versus-host disease. <i>Cell Reports</i> , 2014 , 7, 1809-14	10.6	30

165	Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantation. <i>Theranostics</i> , 2014 , 4, 280-9	12.1	36
164	Acquisition of an immunosuppressive protumorigenic macrophage phenotype depending on c-Jun phosphorylation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 17582-7	11.5	37
163	Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2014 , 99, 1380-6	6.6	25
162	Single cell analysis exposes intratumor heterogeneity and suggests that FLT3-ITD is a late event in leukemogenesis. <i>Experimental Hematology</i> , 2014 , 42, 457-63	3.1	15
161	Infusion of Donor Lymphocytes Genetically Engineered to Express the Herpes Simplex Virus Thymidine Kinase (HSV-TK) Suicide Gene after Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Preliminary Efficacy Data from the Randomized TK008 Study. <i>Blood</i> , 2014 , 124, 2535-2535	2.2	4
160	Prediction of Allogeneic HSCT Related Mortality in Acute Leukemia: Exploring Boundaries of Prediction through Machine Learning Based Modeling. a Data Mining Study from the Acute Leukemia Working Party (ALWP) of the EBMT. <i>Blood</i> , 2014 , 124, 2568-2568	2.2	1
159	Prevention of Chronic GvHD after HLA-Identical Sibling Peripheral Hematopoietic Stem Cell Transplantation with or without Anti-Lymphocyte Globulin (ATG). Results from a Prospective, Multicenter Randomized Phase III Trial (ATGfamilystudy). <i>Blood</i> , 2014 , 124, 37-37	2.2	9
158	Allogeneic HCT with Reduced Intensity Conditioning Versus Autologous HCT for >55 Years Old Patients with Acute Lymphoblastic Leukemia in First Complete Remission: An Analysis from Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2014 , 124, 3974-3974	2.2	2
157	RIC Allo-SCT with Flu/Bu in Comparison to Flu/Mel for AML Results in Similar Overall Survival: A Report from the ALWP of the EBMT. <i>Blood</i> , 2014 , 124, 545-545	2.2	1
156	Matching of MHC Class I Chain-Related Genes a and B Is Associated with Reduced Incidence of Severe Acute Graft-Versus-Host Disease after Unrelated Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014 , 124, 664-664	2.2	1
155	Randomized Trial of Busulfan with Cyclophosphamide Versus Busulfan with Fludarabine As Preparative Regimen to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia: A Study from the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Blood</i> , 2014 , 124, 727-727	2.2	1
154	Higher Doses of Antithymocyte Globulin (ATG) Increase the Risk of Relapse in Acute Myeloid Leukemia (AML) Patients Undergoing Matched Related Donor Allogeneic Transplantation in First Complete Remission (CR1): An Analysis from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2014 , 124, 700-700	2.2	2
153	BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial. <i>Blood</i> , 2014 , 124, 950-950	2.2	11
152	Efficacy of HSV-TK+ suicide gene donor lymphocytes after haploidentical transplantation (haplo-HSCT): Preliminary results of randomized TK008 study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7003-7003	2.2	1
151	Continuous treatment (CT) versus fixed duration of therapy (FDT) in newly diagnosed myeloma patients: PFS1, PFS2, OS endpoints.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8515-8515	2.2	5
150	Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. <i>Oncotarget</i> , 2014 , 5, 11283-96	3.3	99
149	Early Apoptotic Cells (ApoCell) As Prophylaxis of Graft-Versus-Host Disease in Myeloablative HLA-Matched Allogeneic Bone Marrow Transplantation Is Safe and Effective: 1 Year Follow-up. <i>Blood</i> , 2014 , 124, 5866-5866	2.2	
148	Autologous Stem Cell Transplantation for Primary Mediastinal B Cell Lymphoma in the Rituximab Era: A Retrospective Study By the EBMT Lymphoma Working Party. <i>Blood</i> , 2014 , 124, 1195-1195	2.2	1

147	Influence of Preexisting Invasive Aspergillosis on Allo-HSCT Outcome: A Retrospective EBMT Analysis from the Infectious Diseases and Acute Leukemia Working Parties. <i>Blood</i> , 2014 , 124, 185-185	2.2	
146	Safety and Efficacy of Thiotepa-Based Conditioning Therapy for Allogeneic Transplantation in Acute Myeloid Leukemia - a Survey from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2014 , 124, 3895-3895	2.2	
145	The Hierarchy of Alternative Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Poor Risk AML in CR1: 10/10 Matched Unrelated Donors Still to be Preferred over Haplo-Identical Donors or Umbilical Cord Blood. <i>Blood</i> , 2014 , 124, 681-681	2.2	
144	S1P Modulator FTY720 Targets Multiple Myeloma Cell Proliferation and Stromal Interactions Via CXCR4/CXCL12 and mTOR Pathways. <i>Blood</i> , 2014 , 124, 4707-4707	2.2	
143	Haploidentical Versus Autologous Stem Cell Transplantation in Adult Acute Leukemia: A Matched Pair Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2014 , 124, 2508-2508	2.2	
142	High Risk Advanced Stage Hodgkin Lymphoma Is Well Controlled with 2 Cycles of Escalated Beacopp Followed By 4 Cycles of ABVD in Patients Who Rapidly Achieve Metabolic CR on Interim PET/CT Scan. <i>Blood</i> , 2014 , 124, 4442-4442	2.2	
141	The International Multiple Myeloma Research (IMMENSE) Consortium: Genetics of Multiple Myeloma Risk and Prognosis. <i>Blood</i> , 2014 , 124, 3421-3421	2.2	
140	Allogeneic Hematopoietic Cell Transplantation in AML with Normal Karyotype and NPM1 Mutated FLT3-ITD Negative: A Retrospective Analysis from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2014 , 124, 1230-1230	2.2	0
139	Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome; A More Favorable Outcome after Fludarabine and Treosulfan Conditioning. a Survey on Behalf of the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2014 , 124, 1216-1216	2.2	
138	Unrelated Cord Blood Versus Non-T Cell Depleted Haploidentical Stem Cell Transplantation: Comparable Results in Adults with Acute Leukemia, a Eurocord and ALWP-EBMT Study. <i>Blood</i> , 2014 , 124, 1227-1227	2.2	
137	Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140. <i>Clinical Cancer Research</i> , 2013 , 19, 3495-507	12.9	48
136	Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2519-2526	2.2	116
135	Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. <i>Blood</i> , 2013 , 121, 849-57	2.2	179
134	Immunobiology and Pharmacologic Manipulation of Dendritic and Regulatory Cells. <i>Clinical and Developmental Immunology</i> , 2013 , 2013, 1-2		3
133	Maintenance Therapy With Lenalidomide Significantly Improved Survival Of Yong Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2013 , 122, 2089-2089	2.2	10
132	Thiotepa-Based Vs TBI-Based Myeloablative Conditioning Prior To Allogeneic Stem Cell Transplantation (HSCT) For Acute Myeloid Leukemia (AML) In First Complete Remission (CR1): A Retrospective Analysis From The ALWP Of The EBMT. <i>Blood</i> , 2013 , 122, 2123-2123	2.2	1
131	StemEx (Copper Chelation Based) Ex Vivo Expanded Umbilical Cord Blood Stem Cell Transplantation (UCBT) Accelerates Engraftment and Improves 100 Day Survival In Myeloablated Patients Compared To a Registry Cohort Undergoing Double Unit UCBT: Results Of a Multicenter Study Of 101 Patients With Hematologic Malignancies. <i>Blood</i> , 2013 , 122, 295-295	2.2	19
130	Randomized Placebo-Controlled Phase III Study Of Perifosine Combined With Bortezomib and Dexamethasone In Relapsed, Refractory Multiple Myeloma Patients Previously Treated With Bortezomib. <i>Blood</i> , 2013 , 122, 3189-3189	2.2	4

129	The Use Of Tevagrastim (Biosimilar Filgrastim XMO2) For Hematopoietic Stem Cell Mobilization In HLA Matched Sibling Donors For Allogeneic Stem Cell Transplantation To AML/MDS Patients. <i>Blood</i> , 2013 , 122, 3275-3275	2.2	1
128	The CXCR4 Antagonist BL-8040 Efficiently Induces Apoptosis and Inhibits The Survival Of AML Cells. <i>Blood</i> , 2013 , 122, 3939-3939	2.2	4
127	Treosulfan Based Conditioning Prior To Allogeneic Stem Cell Transplantation (HSCT) For Acute Myelogenous Leukemia (AML): A Retrospective Analysis From The ALWP Of The EBMT. <i>Blood</i> , 2013 , 122, 545-545	2.2	3
126	Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8509-8509	2.2	13
125	Efficacy of radioimmunotherapy-based conditioning with high-dose chemotherapy and autologous stem cell transplantation for transformed lymphoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8556-8556	2.2	
124	Extreme Heterogeneity Of Myeloablative Total Body Irradiation (TBI) Techniques Across Europe: A Survey Of Acute Leukemia Working Party Of The EBMT. <i>Blood</i> , 2013 , 122, 4565-4565	2.2	
123	Prediction Of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Related Mortality In Acute Leukemia: Generation Of a Machine Learning-Based Model Using The Data Set of The Acute Leukemia Working Party (ALWP) Of The EBMT. <i>Blood</i> , 2013 , 122, 409-409	2.2	0
122	Outcome Of Patients With HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma (ATL) Who Have Undergone Stem Cell Transplantation: A Retrospective Study Of The EBMT Lymphoma Working Party. <i>Blood</i> , 2013 , 122, 3398-3398	2.2	
121	Missing HLA C Group 1 Ligand In Patients With AML and MDS Is Associated With Reduced Risk Of Relapse After Allogeneic Stem Cell Transplantation With Fludarabine and Treosulfan Reduced Toxicity Conditioning. <i>Blood</i> , 2013 , 122, 4634-4634	2.2	
120	Donor Cell Derived Leukemia: Description Of 38 Cases and a Case Control Study. <i>Blood</i> , 2013 , 122, 914-914	2.2	
119	Validation of Digital-PCR Analysis through Programmed imatinib Interruption in Q-RT-PCR Negative Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2013 , 122, 4040-4040	2.2	
118	Chemotherapy Dose Adjustment For Obese Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT): A Survey On Behalf Of The ALWP Of The EBMT. <i>Blood</i> , 2013 , 122, 4535-4535	2.2	
117	Favorable Outcome For Patients With Lymphoid Malignancies Following Allogeneic Stem Cell Transplantation Using Fludarabine Treosulfan, Compared With Other Reduced Intensity Conditioning Regimen. <i>Blood</i> , 2013 , 122, 3380-3380	2.2	
116	Jewish Immigrants Of Middle Eastern Origin Have a Lower Incidence Of Multiple Myeloma Compared To Both North African and European Jews In a Cohort Of 746,200 Israeli Men Followed From Late Adolescence. <i>Blood</i> , 2013 , 122, 5346-5346	2.2	
115	Allogeneic Hematopoietic Stem-Cell Transplantation In AML and MDS Using Myeloablative Versus Reduced Intensity Conditioning: 10 Years Later. <i>Blood</i> , 2013 , 122, 4635-4635	2.2	
114	Allogeneic Stem Cell Transplantation For Acute Myeloid Leukemia With Normal Cytogenetics (CN-AML): Outcome, Risk Factors and Role Of Molecular Subgroups In 752 Patients [A Report From The Acute Leukemia Working Party Of EBMT. <i>Blood</i> , 2013 , 122, 921-921	2.2	
113	Mobilized peripheral blood stem cells compared with bone marrow from HLA-identical siblings for reduced-intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working Party of EBMT. <i>European Journal of Haematology</i> , 2012 , 88, 206-13	3.8	18
112	Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1422-9	4.7	46

111	Intratumoral heterogeneity in the self-renewal and tumorigenic differentiation of ovarian cancer. <i>Stem Cells</i> , 2012 , 30, 415-24	5.8	29
110	Nilotinib Exhibits an in Vitro Antiviral Activity Against Human Cytomegalovirus (HCMV): Potential Clinical Applications. <i>Blood</i> , 2012 , 120, 4666-4666	2.2	2
109	Salvage Therapy with the Combination of ARA-C and Gemtuzumab Ozogamicin in Post-Allo-SCT High Risk AML Patients Is Feasible and Results in Modest Responses.. <i>Blood</i> , 2012 , 120, 2629-2629	2.2	
108	Significance of Busulfan Dose Intensity On Outcomes of Hematopoietic Cell Allografting for AML in Second Complete Remission or Beyond: A Report From the EBMT Acute Leukemia Working Party. <i>Blood</i> , 2012 , 120, 1929-1929	2.2	
107	Assessment of the Effect of Nilotinib (Tasigna) Maintenance Therapy After Allogeneic Stem Cell Transplantation in Patients with Advanced CML and Ph+ ALL On Immune Reconstitution and Lymphocyte Function. <i>Blood</i> , 2012 , 120, 4478-4478	2.2	
106	A Sensitive Replicate RQ-PCR of BCR ABL Transcripts Suggests That A Large Portion of Long Term Post Allogeneic SCT CML Patients Are in Deep MR and May Therefore Be Cured From Their Disease. <i>Blood</i> , 2012 , 120, 1690-1690	2.2	
105	Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML in Vitro and in Vivo. <i>Blood</i> , 2012 , 120, 3735-3735	2.2	
104	Treatment of Relapsed AML and MDS After Allogeneic Stem Cell Transplantation: A Second Transplant From a Different Donor May Be the Most Effective Option. <i>Blood</i> , 2012 , 120, 1963-1963	2.2	
103	Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need. <i>Best Practice and Research in Clinical Haematology</i> , 2011 , 24, 369-479	4.1	41
102	Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 117-23	4.7	45
101	Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients . <i>Blood</i> , 2011 , 118, 3069-3069	2.2	7
100	Nicotinamide, a Form of Vitamin B3, Promotes Expansion of Natural Killer Cells That Display Increased In Vivo Survival and Cytotoxic Activity,. <i>Blood</i> , 2011 , 118, 4035-4035	2.2	9
99	Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial. <i>Blood</i> , 2011 , 118, 480-480	2.2	15
98	Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years,. <i>Blood</i> , 2011 , 118, 3766-3766	2.2	
97	Long-Term Survival and Quality of Life Assessment After Allogeneic Stem-Cell Transplantation; Comparable Results Following Myeloablative and Reduced-Intensity Conditioning,. <i>Blood</i> , 2011 , 118, 4096-4096	2.2	
96	CXCR4 Promotes the Tumorigenicity of Multiple Myeloma, Including Increased Motility, Clonogenicity, up-Regulation of VLA-4, Protection From Chemotherapy and Aggressive Tumor Development In Vivo. <i>Blood</i> , 2011 , 118, 1801-1801	2.2	
95	Clofarabine Containing Conditioning Regimen for Allo-SCT in AML/ALL Patients: A Survey From the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2011 , 118, 3004-3004	2.2	
94	Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. <i>British Journal of Haematology</i> , 2010 , 148, 323-31	4.5	52

93	Immunotherapy for B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2010 , 51, 7-9	1.9	
92	Introduction: advances and promise in human umbilical cord blood. <i>Best Practice and Research in Clinical Haematology</i> , 2010 , 23, 169-70	4.2	
91	A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation. <i>Journal of Immunotherapy</i> , 2010 , 33, 326-33	5	12
90	The aberrant asynchronous replication - characterizing lymphocytes of cancer patients - is erased following stem cell transplantation. <i>BMC Cancer</i> , 2010 , 10, 230	4.8	9
89	Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up. <i>Cancer</i> , 2010 , 116, 3621-30	6.4	42
88	BKT140 Is a Novel CXCR4 Antagonist with Stem Cell Mobilization and Antimyeloma Effects: An Open-Label First Human Trial In Patients with Multiple Myeloma Undergoing Stem Cell Mobilization for Autologous Transplantation. <i>Blood</i> , 2010 , 116, 2260-2260	2.2	9
87	Adaptor Protein LNK Binds to and Is Phosphorylated by JAK3 and May Serve as a Scaffold for JAK3 Autophosphorylation In the Absence of An Appropriate Cytokine Receptor. <i>Blood</i> , 2010 , 116, 2785-2785	2.2	2
86	Fludarabine and Treosulfan Conditioning for Allogeneic Stem-Cell Transplantation; a Dose- Intense Regimen with Limited Toxicity.. <i>Blood</i> , 2010 , 116, 3473-3473	2.2	3
85	Matched Unrelated Donor Transplantation Is Curative In Selected Patients with Diffuse Large B Cell Lymphoma: A Report of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2010 , 116, 363-363	2.2	1
84	Ex Vivo Generated Donor Central Memory CD8 T Cells, Previously Shown to Enhance Engraftment of Allogeneic Bone Marrow, Also Exhibit Significant GVL Activity without Causing Gvhd In An In Vivo b Cell Lymphoma Model. <i>Blood</i> , 2010 , 116, 424-424	2.2	2
83	Halofuginone Induces Post-Transcriptional Down-Regulation of Cyclin D1, Cell Cycle Arrest and Apoptosis In Mantle Cell Lymphoma Cells through Activation of Integrated Stress Response Pathways. <i>Blood</i> , 2010 , 116, 773-773	2.2	0
82	The Impact of Center Experience on Results of Reduced Intensity [Allogeneic Hematopoietic Stem Cell Transplantation. A Survey From the Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2010 , 116, 3517-3517	2.2	
81	Donor Lymphocyte Infusions and Second Transplantation as Salvage Treatment for Relapsed Myelofibrosis After Reduced-Intensity allografting.. <i>Blood</i> , 2010 , 116, 1300-1300	2.2	
80	A Multi-Center Prospective Randomized Study Comparing Ibritumomab Tiuxetan (Zevalin) and High-Dose BEAM Chemotherapy (Z-BEAM) Vs. BEAM Alone as the Conditioning Regimen Prior to Autologous Stem-Cell Transplantation In Patients with Aggressive Lymphoma; Possible Advantage for Z-BEAM In Low-Risk Patients. <i>Blood</i> , 2010 , 116, 686-686	2.2	1
79	Older Patients with Normal Cytogenetics AML Have a Higher Rate of Genomic Changes Compared to Young Patients as Determined by SNP Chip Analysis. <i>Blood</i> , 2010 , 116, 2479-2479	2.2	
78	Cyclosporine and Methotrexate Compared with Cyclosporine and Mycophenolate Mofetil as GVHD Prevention Regimens In Allogeneic Stem-Cell Transplantation From Unrelated Donors; Relative Outcomes Are Dependant on Disease Status at Transplantation. <i>Blood</i> , 2010 , 116, 2314-2314	2.2	
77	Analysis of the Crosstalk Between TGF- β /VEGF-Angiogenesis in an In Vivo Model of Acute Promyelocytic Leukemia. <i>Blood</i> , 2010 , 116, 1845-1845	2.2	
76	Cig-FISH-Analysis of Extramedullary Myeloma Manifestations Shows Similar Incidence of Prognostic Genetic Aberrations Compared to Bone Manifestations or Soft Tissue Involvement. <i>Blood</i> , 2010 , 116, 4993-4993	2.2	

75	Allogeneic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia After Prior Treatment with Nilotinib or Dasatinib. <i>Blood</i> , 2010 , 116, 2348-2348	2.2	
74	Second Allogeneic Stem Cell Transplantation (allo-SCT) Using Reduced-Intensity Conditioning (RIC) for Acute Myeloid Leukemia (AML) Patients Who Relapsed Following a First RIC Allo-SCT: a Survey From the Acute Leukemia Working Party of EBMT.. <i>Blood</i> , 2010 , 116, 3447-3447	2.2	
73	Attempt to Discontinue Imatinib Following Interferon Alfa Pre-Treatment In Chronic Phase CML Patients Achieving Stable Complete Cytogenetic Responses (CCyR). <i>Blood</i> , 2010 , 116, 4898-4898	2.2	
72	Combining the Ras Inhibitor Salirasib and Proteasome Inhibitors: A Potential Treatment for Multiple Myeloma. <i>Blood</i> , 2010 , 116, 1810-1810	2.2	
71	Recent developments in human umbilical cord blood transplantation in Israel. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 99-103	4-7	
70	Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2009 , 114, 5264-70	2.2	309
69	Comparison of Outcomes After Allogeneic HSCT for Adult Patients with AML in Remission Using in the Conditioning Regimen Either I.V. Busulfex (BU) Plus Cyclophosphamide (Cy) or TBI Plus Cy: An-ALWP-EBMT Survey.. <i>Blood</i> , 2009 , 114, 195-195	2.2	
68	Allogeneic Hematopoietic Stem-Cell Transplantation with Reduced-Intensity Conditioning in Patients with Refractory and Relapsing Multiple Myeloma: Long-Term Follow-up.. <i>Blood</i> , 2009 , 114, 3359-3359	2.2	
67	Prior Response to Imatinib Predicts Response to Second Line Treatment with Nilotinib in CML Patients Resistant or Intolerant to Imatinib.. <i>Blood</i> , 2009 , 114, 3297-3297	2.2	
66	Prevalence and Prognostic Impact of Allelic Imbalances Associated with Leukemic Transformation of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.. <i>Blood</i> , 2009 , 114, 1280-1280	2.2	
65	Umbilical Cord Blood Cells for Cardiac Repair 2008 , 59-72		
64	A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. <i>Blood</i> , 2008 , 112, 3574-81	2.2	242
63	Interest of Non-Myeloablative Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma: A Multicenter Retrospective Study.. <i>Blood</i> , 2008 , 112, 1965-1965	2.2	1
62	Improvement of Oxidative Stress Parameters in MDS Patients with Iron Overload Treated with Deferasirox. <i>Blood</i> , 2008 , 112, 2675-2675	2.2	10
61	Reduced Intensity Versus Conventional Myeloablative Conditioning (RIC vs. MAC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Lymphoblastic Leukemia (ALL): A Survey from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2008 , 112, 793-793	2.2	2
60	Outcome after Allogeneic Stem Cell Transplantation for Adult Acute Myeloid Leukaemia Patients Exhibiting Isolated or Associated Trisomy 8 Chromosomal Abnormality: A Survey on Behalf of the Acute Leukemia Working Party (ALWP) of the EBMT.. <i>Blood</i> , 2008 , 112, 1129-1129	2.2	
59	Two Distinct Populations of Enriched Non Mobilized Peripheral Blood Mononuclear Cells (PBMNCs) with Different Functional Capacities. <i>Blood</i> , 2008 , 112, 5402-5402	2.2	
58	Experimental Double Cord Blood Transplantation (DCBT) of An Expanded Unit Together with a Non-Manipulated Unit in NOD/SCID Mice.. <i>Blood</i> , 2008 , 112, 2313-2313	2.2	

57	Somatic Expansion of the Frataxin Gene GAA Repeats in MDS Patients.. <i>Blood</i> , 2008 , 112, 1642-1642	2.2	
56	P-Glycoprotein (Pgp) - Dependent Drug Resistance to Imatinib at CML-BC Is Exclusively Developed in Aggressive Minor Blast Subpopulation (MS) and Can Be Reversed by Pgp Modulators. <i>Blood</i> , 2008 , 112, 721-721	2.2	1
55	Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2007 , 48, 2352-9	1.9	43
54	Effect of halofuginone, a collagen alpha1(I) inhibitor, on wound healing in normal and irradiated skin: implication for hematopoietic stem cell transplantation. <i>Acta Haematologica</i> , 2007 , 118, 77-83	2.7	10
53	Combination of Rituximab with Initial Chemotherapy Improves Outcome of Primary Mediastinal B-Cell Lymphoma: A Retrospective Analysis of a Single Institution Cohort. <i>Blood</i> , 2007 , 110, 1283-1283	2.2	3
52	Human Placental Derived Mesenchymal Stromal Cells (MSC) Grown in 3D-Culture (PLX-I), Promotes Engraftment of Human Umbilical Cord Blood (hUCB) Derived CD34+ Cells in NOD/SCID Mice.. <i>Blood</i> , 2007 , 110, 1416-1416	2.2	2
51	Combined escBEACOPP-ABVD Therapy for Advanced Hodgkin's Lymphoma Patients with High IPS Score: An Effective Regimen and Low Positive Predictive Value of Early FDG-PET/CT Scan.. <i>Blood</i> , 2007 , 110, 2319-2319	2.2	1
50	A Prospective Study of Imatinib 400 mg vs 800 mg Frontline in High Risk Ph+ Chronic Myeloid Leukemia (CML) Patients.. <i>Blood</i> , 2007 , 110, 26-26	2.2	2
49	Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib ± Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 2735-2735	2.2	1
48	Halofuginone Exerts Antiproliferative and Antiangiogenic Actions on Acute Promyelocytic Leukemia Cells through Modulation of the TGFβ Pathway.. <i>Blood</i> , 2007 , 110, 2850-2850	2.2	1
47	The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure.. <i>Blood</i> , 2007 , 110, 410-410	2.2	2
46	A Phase I Study of INNO-406 in Patients with Advanced Philadelphia (Ph+) Chromosome-Positive Leukemias Who Are Resistant or Intolerant to Imatinib and Second Generation Tyrosine Kinase Inhibitors.. <i>Blood</i> , 2007 , 110, 469-469	2.2	9
45	LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma in the Pre- and Post-Rituximab Treatment Eras.. <i>Blood</i> , 2007 , 110, 52-52	2.2	2
44	Prognostic Significance of VEGF, VEGF Receptors, and Microvessel Density in Diffuse Large B Cell Lymphoma Treated with Anthracycline-Based Chemotherapy.. <i>Blood</i> , 2007 , 110, 53-53	2.2	3
43	Dose-Reduced Conditioning Followed by Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis. Results from a Multicenter Prospective Trial of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).. <i>Blood</i> , 2007 , 110, 683-683	2.2	9
42	3D Grown Human Placental-Derived Mesenchymal Stromal Cells (PLX-I) Support and Potentiate the Engraftment of Human Cord Blood Unfractionated (UFCBC) and Fractionated CD34+ Cells (hCD34+) in Irradiated NOD/SCID Mice.. <i>Blood</i> , 2007 , 110, 4104-4104	2.2	
41	Relapse of Acute Myeloid Leukemia after Allogeneic Stem-Cell Transplantation (SCT) with Myeloablative Conditioning Is Associated with Longer Survival Than Relapse after Reduced-Intensity Conditioning (RIC).. <i>Blood</i> , 2007 , 110, 1650-1650	2.2	
40	Transformation to Myelofibrosis and Blastic Transformation of PV Are Associated with Higher JAK2 Mutation Levels.. <i>Blood</i> , 2007 , 110, 1555-1555	2.2	

39	Effect of Disease Stage and Time Since Diagnosis on Time to Progression for Pegylated Liposomal Doxorubicin + Bortezomib vs Bortezomib Alone in Relapsed or Refractory Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 2740-2740	2.2	
38	High Response Rate and Improved Graft-Versus-Host Disease (GVHD) Following Bortezomib as Salvage Therapy after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation (RIC allo-SCT) for Multiple Myeloma (MM).. <i>Blood</i> , 2007 , 110, 1080-1080	2.2	
37	Reduced-Intensity Conditioning Is Associated with Shorter Duration of Chronic GVHD Than Myeloablative Conditioning and Provides Very Good Quality of Life for Long-Term Survivors after Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2007 , 110, 1668-1668	2.2	
36	Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation (SCT) with Fludarabine and Intravenous Busulfan Is Associated with Improved Toxicity Profile and Longer Survival Than Conditioning with Fludarabine and Melphalan in Patients with Chemo-Sensitive Hematological Malignancies.. <i>Blood</i> , 2007 , 110, 2002-2002	2.2	
35	MT1-MMP and RECK Inversely Regulate Hematopoietic Progenitor Cell Egress.. <i>Blood</i> , 2007 , 110, 1259-1259		
34	Low Levels of Circulating CS1, a Newly Identified Multiple Myeloma (MM) Antigen for a Novel Humanized HuLuc63 Monoclonal Antibody, Is Detected in MM Patient Sera and Correlates with Active Disease.. <i>Blood</i> , 2007 , 110, 1509-1509	2.2	1
33	Nicotinamide Modulates Ex-Vivo Expansion of Cord Blood Derived CD34+ Cells Cultured with Cytokines and Promotes Their Homing and Engraftment in SCID Mice.. <i>Blood</i> , 2006 , 108, 725-725	2.2	7
32	Imatinib High Dose (800 mg): Results of a Phase II Trial of the GIMEMA (Gruppo Italiano Malattie Ematologiche Dell'Adulto) CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.. <i>Blood</i> , 2006 , 108, 4776-4776	2.2	
31	No Evidence for Increased Transplant Related Complications in Ph+ Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia with Prior Treatment with Dasatinib.. <i>Blood</i> , 2006 , 108, 2975-2975	2.2	
30	Towards Stopping Imatinib Therapy under the Umbrella of Interferone: Alpha-Interferone Improves Molecular Response in CML Patients with Imatinib Induced Complete Cytogenetic Remission: An Early Observation from a Study of Pegylated Interferone in the Set up of Minimal Residual Disease.. <i>Blood</i> , 2006 , 108, 4769-4769	2.2	
29	Expansion of Hematopoietic Stem Cells (HSC) from Cord-Blood (CB) Derived Mononuclear Cells (MNC) in Cytokine-Free Environment Using Mesenchymal Cells Spatial Co-Culture System.. <i>Blood</i> , 2006 , 108, 2565-2565	2.2	
28	Comparison between Two Reduced-Intensity Conditioning Regimens Prior to Allogeneic Stem Cell Transplantation: Fludarabine and Melphalan Is Associated with Higher Incidence of Acute Graft-Versus-Host Disease and Non-Relapse Mortality and Lower Incidence of Relapse Than	2.2	
27	No Adverse Impact of 13q14 and P53 Deletion, t(4;14)(p16;q32) or Overrepresentation of CMYC(8q24) as Detected by Fluorescence In Situ Hybridization on Outcome in Patients with Multiple Myeloma Following Dose-Reduced Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2006 , 108, 5038-5038	2.2	
26	Malignant Progression of Human CML Clone Demonstrates a Unique Developmental Pathway Characterized by Altered Expression Pattern of Cancer, Adhesion and Drug Resistance Genes.. <i>Blood</i> , 2006 , 108, 4293-4293	2.2	
25	Functional CXCR4 Expressing Microparticles and SDF-1 Correlate with Circulating AML Cell Counts.. <i>Blood</i> , 2006 , 108, 4375-4375	2.2	
24	The Oncoprotein LMO2 Is Expressed in a Germinal Center B-Cell-Associated Pattern and Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2006 , 108, 810-810	2.2	
23	Near-Tetraploidy Can Mask the Presence of Chromosome 13q Deletions in Plasma Cells of Patients with Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 4280-4280	2.2	
22	Donor C3435T Polymorphism in the Multidrug Resistance 1 (MDR1) Gene Is Associated with the Incidence of Acute and Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2006 , 108, 2868-2868	2.2	

21	Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. <i>Blood</i> , 2005 , 105, 4532-9	2.2	206
20	Allogeneic Hematopoietic Stem-Cell Transplantation in AML and MDS Using Myeloablative Versus Reduced Intensity Conditioning: The Role of Dose-Intensity.. <i>Blood</i> , 2005 , 106, 47-47	2.2	2
19	Ibritumomab Tiuxetan (Zevalin) in the Conditioning Regimen for Autologous and Reduced-Intensity Allogeneic Stem-Cell Transplantation in Patients with Chemo-Refractory Non-Hodgkin Lymphoma.. <i>Blood</i> , 2005 , 106, 1131-1131	2.2	1
18	Persistent Mixed Chimerism in Plasma Cells Following Allogeneic Stem-Cell Transplantation in Patients with Acute Leukemia Is a Surrogate Marker for Leukemia Relapse.. <i>Blood</i> , 2005 , 106, 2749-2749 ^{2,2}		
17	Spontaneous Pregnancy and Fertility Preservation Program in Women Undergoing High Dose Chemotherapy for Hematological Malignancies.. <i>Blood</i> , 2005 , 106, 1114-1114	2.2	
16	Down-Regulation of Activin A by Lymphoma: A Possible Mechanism of Bone Marrow Involvement.. <i>Blood</i> , 2005 , 106, 4669-4669	2.2	
15	Imatinib 800 mg: Preliminary Results of a Phase II Trial of the GIMEMA CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients. <i>Blood</i> , 2005 , 106, 1098-1098	2.2	
14	Outcomes after HLA-Identical Sibling Allogeneic Peripheral Blood Stem Cell Transplantation Using Reduced Intensity Conditioning Compared to Autologous Peripheral Blood Stem Cell Transplantation for Elderly Patients with De Novo Acute Myeloid Leukemia.. <i>Blood</i> , 2005 , 106, 43-43	2.2	
13	Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. <i>Experimental Hematology</i> , 2004 , 32, 122-30	3.1	79
12	Membrane Type 1-Matrix Metalloproteinase Is Directly Involved in G-CSF Induced Human Hematopoietic Stem and Progenitor Cell Mobilization.. <i>Blood</i> , 2004 , 104, 2675-2675	2.2	6
11	Glucocerebrosidase Alleviates Chronic Graft-Versus-Host-Disease in a Murine Model.. <i>Blood</i> , 2004 , 104, 4965-4965	2.2	
10	CD45 Phosphatase Is Involved in Motility and Development of Hematopoietic Stem and Maturing Cells by the Regulation of Cell Adhesion and Cytokine Signaling.. <i>Blood</i> , 2004 , 104, 119-119	2.2	2
9	Cell Cycle Progression and Self-Renewal Divisions of Cord Blood Derived CD34+ Cells Treated with the Polyamine Copper-Chelator Tetraethylenepentamine.. <i>Blood</i> , 2004 , 104, 4237-4237	2.2	
8	Motility, Proliferation and Egress of Human AML Cells in Transplanted NOD/SCID Mice Are Regulated by Membrane Bound and Secreted Elastase.. <i>Blood</i> , 2004 , 104, 3379-3379	2.2	
7	A Pilot Study of Combined Escalated BEACOPP-ABVD Therapy for Advanced Hodgkin Lymphoma Patients with High IPS Score: The Israel Cooperative Lymphoma Group.. <i>Blood</i> , 2004 , 104, 4576-4576	2.2	
6	Comparison between Anti-Thymocyte Globulin and Alemtuzumab and the Possible Impact of KIR-Ligand Mismatch in Melphalan/Fludarabine Dose-Reduced Conditioning Followed by HLA-Matched and Mismatched Unrelated Stem Cell Transplantation in Patients with Multiple Myeloma. <i>Blood</i> , 2004 , 104, 666-666	2.2	
5	Abdominal CT in the Clinical Evaluation of Acute Graft-Versus-Host Disease of the Gastrointestinal Tract: Diffuse Small Intestine Involvement Is Associated with Severity and Outcome.. <i>Blood</i> , 2004 , 104, 5073-5073	2.2	
4	Ex-Vivo Expanded Human Bone Marrow-Derived AC133+ Cells To Treat Myocardial Infarction.. <i>Blood</i> , 2004 , 104, 154-154	2.2	

- 3 Nicotinamide, a Potent SIRT2 Inhibitor, Delays Differentiation of Hematopoietic Progenitor Cells.. *Blood*, **2004**, 104, 4142-4142 2.2
- 2 Low Dose Thalidomide and Donor Lymphocyte Infusion as Adoptive Immunotherapy after Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma.. *Blood*, **2004**, 104, 1646-1646 2.2
- 1 Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. *Blood*, **2002**, 100, 3919-24 2.2 160